Evaluation of zonulin levels in patients with migraine

Basit Öğe Kaydı
dc.authoridUlfer, Gozde/0000-0003-2350-6381
dc.authoridCakici, Cagri/0000-0002-8662-5284
dc.authoridyabalak, ahmet/0000-0002-3317-9567;
dc.contributor.authorUlfer, Gozde
dc.contributor.authorPolat, Burcu
dc.contributor.authorYabalak, Ahmet
dc.contributor.authorCakici, Cagri
dc.date.accessioned2025-10-11T20:48:10Z
dc.date.available2025-10-11T20:48:10Z
dc.date.issued2025
dc.departmentDüzce Üniversitesien_US
dc.description.abstractBackground Zonulin regulates permeability in blood-brain and intestinal barriers. The pathophysiology of migraine is based on the effect of neurogenic inflammation. The aim of the current investigation was to examine the serum zonulin level in individuals suffering from migraine. Methods The sample comprised 40 individuals who had migraine and 40 controls. Disease duration, attack duration, attack frequency, Visual Analog Scale (VAS) scores, and comorbidities were available for the migraine group. Serum zonulin levels were evaluated by using the ELISA method. Results There were no statistically significant differences between the two groups concerning age or gender (p > 0.05). The zonulin value of patients with migraine was higher when compared to the controls, indicating a significant difference (p = 0.037; p < 0.05). The zonulin level did not correlate with disease duration, attack duration, VAS score, or attack frequency (p > 0.05). The receiver operating characteristic curve analysis of zonulin revealed a cut-off value of 30.58 and above, at which it had 52.50% sensitivity, 77.5% specificity, 70% positive predictive value, and 62% a negative predictive value. The area under the curve was 63.6%, and the standard error value was 6.3%. The analysis also showed a statistically significant correlation between migraine diagnosis and a zonulin level of 30.58 (p = 0.006; p < 0.01). Conclusions Elevated zonulin levels in patients with migraine support the disruption of the intestinal barrier and neuroinflammation in these patients. The zonulin level may be a predictive biomarker of migraine. Multicenter, randomized trials are needed to evaluate treatments for intestinal permeability and zonulin levels in migraine patients.en_US
dc.identifier.doi10.1186/s12883-025-04058-y
dc.identifier.issn1471-2377
dc.identifier.issue1en_US
dc.identifier.pmid39905280en_US
dc.identifier.scopus2-s2.0-85218037629en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1186/s12883-025-04058-y
dc.identifier.urihttps://hdl.handle.net/20.500.12684/21757
dc.identifier.volume25en_US
dc.identifier.wosWOS:001414302500003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmcen_US
dc.relation.ispartofBmc Neurologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250911
dc.subjectZonulinen_US
dc.subjectMigraineen_US
dc.subjectHeadacheen_US
dc.subjectGut-brain axisen_US
dc.subjectIntestinal permeabilityen_US
dc.titleEvaluation of zonulin levels in patients with migraineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu